ELAB
Elevai Labs, Inc. Common Stock
NASDAQ: ELAB · HEALTHCARE · BIOTECHNOLOGY
$1.88
-8.88% today
Updated 2026-06-05
Market cap
$7.00M
P/E ratio
—
P/S ratio
5.50x
EPS (TTM)
$-150.06
Dividend yield
—
52W range
$2 – $267
Volume
8.9M
Elevai Labs, Inc. Common Stock (ELAB) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
0 of 8
Last 8 quarters
Avg EPS surprise
—
Last 4 quarters
Revenue YoY growth
+347.6%
Most recent quarter
EPS YoY growth
-285.3%
Most recent quarter
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-2.9%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
-8.2%
2026-03-26
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-05-14 | $-11.17 | — | $1.98 | $2.08 | +5.1% |
| 2026-03-26 | $-51.92 | — | $1.82 | $1.67 | -8.2% |
| 2025-11-14 | $-4.95 | — | $5.51 | $5.21 | -5.4% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2026-03-31 | — | $-11.17 | — | $681994.00 | +347.6% |
| 2025-12-31 | — | $-51.92 | — | $304136.00 | — |
| 2025-09-30 | — | $-4.95 | — | $285948.00 | -45.8% |
| 2025-06-30 | $0.00 | $-8.44 | — | — | — |
| 2025-03-31 | — | $-2.90 | — | $152381.00 | -75.2% |
| 2024-09-30 | — | $-94.85 | — | $527478.00 | — |
| 2024-06-30 | — | $-9,077.70 | — | $605529.00 | — |
| 2024-03-31 | — | $-9,481.84 | — | $614563.00 | — |
| 2023-12-31 | — | $-7,857.70 | — | $698591.00 | — |
Frequently asked questions
Has Elevai Labs, Inc. Common Stock beaten earnings estimates?
Elevai Labs, Inc. Common Stock has beaten Wall Street EPS estimates in 0 of its last 8 quarterly reports. A consistent beat record suggests management guides conservatively and the business has predictable momentum, which tends to support the stock through earnings season.
How does ELAB stock react to earnings?
ELAB has moved an average of -2.9% the day after earnings over its last 3 reports, finishing higher after 1 of them. Next-day moves show how the market digests results in the short term, and repeated dips on strong reports usually mean expectations were already priced in.
What is Elevai Labs, Inc. Common Stock's revenue growth rate?
Elevai Labs, Inc. Common Stock reported year-over-year revenue growth of +347.6% in its most recent quarter, with EPS up -285.3%. Reading revenue growth alongside margins shows whether that growth is translating into profit.